FDA approval, fundraising, and the reality of building in healthcare according to BioticsAI founder
Key takeaways
- Founders building in the healthcare space can’t just build fast and break things.
- That’s exactly the reality Robhy Bustami, co-founder and CEO of Biotics AI, has been building in.
- The team built an early, functioning version of the product for under $100,000, an almost unheard-of milestone in the medical device world.
Founders building in the healthcare space can’t just build fast and break things. Timelines stretch longer, stakes are higher, and success depends on navigating systems that reward rigor over speed.
That’s exactly the reality Robhy Bustami, co-founder and CEO of Biotics AI, has been building in. His company is developing an AI copilot for ultrasound that helps detect fetal abnormalities, an area where misdiagnosis rates remain surprisingly high. Bustami joined Isabelle Johannessen on Build Mode to discuss how the company has navigated a highly regulated space and kept the team motivated while cutting through all the red tape.
BioticsAI started scrappy. The team built an early, functioning version of the product for under $100,000, an almost unheard-of milestone in the medical device world. That prototype helped them win TechCrunch Startup Battlefield in 2023, bringing early visibility and credibility. In January, they gained FDA approval, which means they can begin launching in hospitals and growing the business at a new rate.